Cargando…

A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States

INTRODUCTION: Migraine is associated with considerable disability for patients not adequately managed with current standards of care. New acute therapies may offer relief for this population of patients; however, population size and associated potential costs of new therapies are unclear. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Linda, L’Italien, Gilbert, O’Connell, Thomas, Hasan, Zacharia, Hutchinson, Susan, Lucas, Sylvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478730/ https://www.ncbi.nlm.nih.gov/pubmed/34057676 http://dx.doi.org/10.1007/s12325-021-01781-z

Ejemplares similares

Real‐world assessment of the relationship between migraine‐related disability and healthcare costs in the United States
por: Harris, Linda, et al.
Publicado: (2022)

Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies
por: Harris, Linda, et al.
Publicado: (2023)

Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
por: Johnston, Karissa M., et al.
Publicado: (2021)

A stated preference survey to explore patient preferences for novel preventive migraine treatments
por: Hubig, Lena T., et al.
Publicado: (2022)

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine
por: Popoff, Evan, et al.
Publicado: (2021)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
por: Johnston, Karissa, et al.
Publicado: (2022)

Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
por: Powell, Lauren C., et al.
Publicado: (2022)

Measuring interictal burden among people affected by migraine: a descriptive survey study
por: Hubig, Lena T., et al.
Publicado: (2022)

Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
por: Lo, Siu Hing, et al.
Publicado: (2022)

Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
por: Boscoe, Audra N., et al.
Publicado: (2019)

Estimating the Number of Patients Eligible for Carbon Ion Radiotherapy in the United States
por: Malouff, Timothy D., et al.
Publicado: (2020)

Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study
por: Sapra, Sandhya, et al.
Publicado: (2014)

Measurement properties of the Flu-Like Symptom Index from the Hepatitis Physical Symptom Severity Diary
por: Mathias, Susan, et al.
Publicado: (2013)

The burden of medication overuse headache and patterns of switching and discontinuation among triptan users: a systematic literature review
por: Deighton, Alison M., et al.
Publicado: (2021)

The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
por: Hanssens, Linda, et al.
Publicado: (2008)

Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: a Markov model simulation
por: Budd, David, et al.
Publicado: (2011)

Review of patient-reported outcome measures in chronic hepatitis C
por: Kleinman, Leah, et al.
Publicado: (2012)

Disparities in effective contraceptive use in the United States among individuals dually eligible for Medicare and Medicaid
por: Rodriguez, Maria I., et al.
Publicado: (2023)

Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome
por: Ryan, Michael, et al.
Publicado: (2019)

Patient Eligibility for Transoral Endocrine Surgery Procedures in the United States
por: Grogan, Raymon H., et al.
Publicado: (2019)

The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression
por: Tepper, Stewart J., et al.
Publicado: (2023)

Sponsorship of oncology clinical trials in the United States according to age of eligibility
por: Neel, Dylan V., et al.
Publicado: (2020)

Supplemental Nutrition Assistance Program Eligibility and HIV Incidence in the United States
por: Richterman, Aaron, et al.
Publicado: (2021)

State-Level Variability in Hospital Presumptive Eligibility Programs
por: Gibson, Alexander B., et al.
Publicado: (2023)

Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of Their Diagnosis: A Patient Survey
por: DiBonaventura, Marco daCosta, et al.
Publicado: (2014)

Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
por: Shen, Miles, et al.
Publicado: (2022)

Outcomes after ischemic stroke for dual-eligible Medicare-Medicaid beneficiaries in the United States
por: Leifheit, Erica C., et al.
Publicado: (2023)

Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States
por: Shin, Doosup, et al.
Publicado: (2018)

Estimation of new HIV diagnosis rates among high‐risk, PrEP‐eligible individuals using HIV surveillance data at the Metropolitan Statistical Area level in the United States
por: Mera, Robertino, et al.
Publicado: (2019)

Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States
por: Zhang, Shumin, et al.
Publicado: (2016)

Lung Cancer Screening Eligibility and Screening Patterns Among Black and White Adults in the United States
por: Lozier, Jessica W., et al.
Publicado: (2021)

C-MYC–induced Apoptosis in Polycystic Kidney Disease Is Bcl-2 and p53 Independent
por: Trudel, Marie, et al.
Publicado: (1997)

Reliability and Validity of the 6‐Minute Walk Test in Hypophosphatasia
por: Phillips, Dawn, et al.
Publicado: (2019)

Estimating the number of UK stroke patients eligible for endovascular thrombectomy
por: McMeekin, Peter, et al.
Publicado: (2017)

Nationwide Estimation of Eligibility for Endovascular Thrombectomy Based on the DAWN Trial
por: Lee, Keon-Joo, et al.
Publicado: (2018)

Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia
por: Brent, Robert J.
Publicado: (2018)

Prevention of tuberculosis in household members: estimates of children eligible for treatment
por: Hamada, Yohhei, et al.
Publicado: (2019)

Voluntary assisted dying: estimating life expectancy to determine eligibility
por: Nahm, Sharon H, et al.
Publicado: (2022)

Voluntary assisted dying: estimating life expectancy to determine eligibility
por: Nahm, Sharon H, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgq3g7o121o5c9t3eshf1ld295